http://web.archive.org/web/20130129012830id_/http://www.dailymail.co.uk:80/health/article-2226445/NICE-approves-drugs-transform-chances-surviving-dangerous-form-skin-cancer.html

by @entity0 published : 20:20 est , 1 november 2012 updated : 20:20 est , 1 november 2012 two new drugs that will transform the chances of surviving malignant melanoma , the most dangerous form of skin cancer , are to be approved for use by the @entity7			0
doctors claim ipilimumab and vemurafenib are the first major advance in treatment for 30 years because they increase survival for patients with advanced disease			1
ipilimumab extends lifespan by an average of almost four months in trials on patients where the cancer has spread to other organs - who have no other options			2
but some patients are alive many years later			2
it 's estimated the drugs could help up to 1,000 patients in the @entity29 each year , many of them in their 20s and 30s it is estimated the drugs could benefit up to 1,000 patients in the @entity29 each year , many of them in their 20s and 30s			1
the decision is a u-turn by the @entity36 ( @entity36 ) which originally rejected their use on the @entity7 , saying they were too expensive			1
top doctors wrote to prime minister @entity39 to protest about the proposed ban			0
@entity36 says it has since received additional data about the cost effectiveness of the drugs and is recommending them on the basis that the manufacturers will give the @entity7 a discount			1
ipilimumab costs £ 18,000 for a course of treatment and vemurafenib , also known as zelboraf , costs £ 1,750 a month			1
dr @entity53 , senior lecturer in @entity54 , the @entity55 , one of the leading trial centres for ipilimumab in the @entity29 , said ‘ after 30 years of no progress in the treatment of this terrible illness , this represents a genuine step change in the management of this disease			1
’ trials show ipilimumab , also known as @entity68 and made by @entity69 , increases lifespan by an average of almost four months in patients where the cancer has spread to other organs ,			0
but @entity29 doctors carrying out trials say up to one in four patients is still alive four years after treatment			1
@entity80 , made by @entity81 , works in patients who have a cancer - causing form of the braf gene , around half of cases			0
more than 10,400 people are diagnosed with malignant melanoma each year and 2,000 people die			0
it is the most common kind of cancer for women in their 20s patients in trials lived an average of 13.2 months compared with 9.6 months for patients receiving standard chemotherapy , but other research from @entity100 and @entity101 showed it nearly doubled average survival times to around 16 months			1
both drugs have been paid for by the @entity104 in @entity105 , set up by the government to make drugs available which are awaiting approval or have been rejected by @entity36			1
the @entity104 does not operate in @entity109 , @entity110 and @entity111 where the drugs have not been available			0
dr @entity53 said ‘ if @entity36 had not approved these drugs and they had been withdrawn , it would have been a disaster			2
‘ i think patient power made the difference , @entity36 listened to patients and their families about how little hope there was before these drugs came along			1
’ professor @entity120 , chief executive of the @entity122 - based @entity121 , said ‘ we are delighted that @entity80 , which the @entity121 helped to make possible , is now to become available on the @entity7			0
‘ it represents a great stride forward in the treatment of advanced malignant melanoma , and is a brilliant example of what new - generation targeted cancer therapies can achieve			0
’ @entity131 , of the patient support group factor 50 , said ‘ this is very welcome news for patients with advanced melanoma , who have waited such a long time for any new treatment options that have the potential to extend life			2
‘ the important thing now will be for positive guidance to be implemented as soon as possible so that suitable patients can be given a chance to benefit from this treatment			2
’ more than 10,400 people are diagnosed with malignant melanoma each year and 2,000 people @entity147 is the most common kind of cancer for women in their 20s			0
professor @entity151 , director at the @entity152 at @entity36 , said ‘ for many years the treatments available for this condition have been very limited and in some cases restricted to palliative care			2
‘ @entity80 and ipilimumab are breakthrough treatments that can potentially significantly affect prognosis for these patients and we are very pleased that the manufacturers have worked with us so that we are now able to recommend them both			0
’ draft guidance approving the drugs for @entity7 use is likely to be finalised in december .			0

doctors claim ipilimumab and vemurafenib are the first major advance in treatment for 30 years because they increase survival for patients with advanced disease
it 's estimated the drugs could benefit up to 1,000 patients in the @entity29 each year , many of them in their 20s and 30s
decision is a u-turn by @entity36 which originally rejected their use , saying they were too expensive

@entity29:UK
@entity80:Vemurafenib
@entity81:Roche
@entity111:Northern Ireland
@entity110:Scotland
@entity152:Health Technology Evaluation Centre
@entity151:Carole Longson
@entity131:Gill Nuttall
@entity0:Jenny Hope
@entity7:NHS
@entity53:Lorigan
@entity55:Christie NHS Foundation Trust
@entity54:Medical Oncology
@entity36:NICE
@entity39:David Cameron
@entity100:US
@entity101:Australia
@entity104:Fund
@entity105:England
@entity109:Wales
@entity122:London
@entity120:Alan Ashworth
@entity121:Institute of Cancer Research
@entity147:die.It
@entity68:Yervoy
@entity69:Bristol-Myers Squibb